Your browser doesn't support javascript.
loading
Contrast-enhanced ultrasound is helpful for differentiating benign from malignant parietal pleural lesions.
Findeisen, Hajo; Görg, Christian; Hartbrich, Ruby; Dietrich, Christoph Frank; Görg, Konrad; Trenker, Corinna; Safai Zadeh, Ehsan.
Affiliation
  • Findeisen H; Interdisciplinary Centre of Ultrasound Diagnostics, University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany.
  • Görg C; Interdisciplinary Centre of Ultrasound Diagnostics, University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany.
  • Hartbrich R; Gastroenterology, Endocrinology, Metabolism and Clinical Infectiology, University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany.
  • Dietrich CF; Interdisciplinary Centre of Ultrasound Diagnostics, University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany.
  • Görg K; Department Allgemeine Innere Medizin (DAIM), Kliniken Hirslanden Bern, Beau Site, Salem und Permanence, Bern, Switzerland.
  • Trenker C; Interdisciplinary Centre of Ultrasound Diagnostics, University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany.
  • Safai Zadeh E; Hematology, Oncology and Immunology, University Hospital Giessen and Marburg, Philipps University Marburg, Marburg, Germany.
J Clin Ultrasound ; 50(1): 90-98, 2022 Jan.
Article in En | MEDLINE | ID: mdl-34664724
ABSTRACT

INTRODUCTION:

To describe the value of contrast-enhanced ultrasound (CEUS) for the differentiation of malignant from benign parietal pleural lesions (PPLs). MATERIALS AND

METHODS:

From November 2005 to June 2019, 63 patients with histologically/cytologically confirmed PPLs were investigated by CEUS. On CEUS, the extent of enhancement (EE; marked or reduced/absent) and the homogeneity of enhancement (HE; homogeneous or inhomogeneous) were analyzed retrospectively.

RESULTS:

In total, 24/63 lesions were benign, and 39/63 lesions were malignant. On CEUS, 11/24 benign and 36/39 malignant lesions showed a marked enhancement. A marked enhancement was significantly more frequently associated with malignancy compared with benign lesions (p < 0.001). In five cases, due to the absence of enhancement, it was not possible to determine the HE. In the remaining cases, 9/20 benign and 19/38 malignant lesions showed an inhomogeneous enhancement (p = 0.79).

CONCLUSION:

On CEUS, marked enhancement was significantly more frequently associated with malignant compared with benign lesions. However, some benign lesions, such as chronic inflammatory processes, may also show a marked enhancement. Therefore, the interpretation of perfusion patterns in these lesions must always take into account the clinical background of the patient.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Contrast Media Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Contrast Media Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Year: 2022 Type: Article